Skip to main content

IOV-LUN-202 A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes
(LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

NCT04614103

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes
(LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Iovance

This study is being conducted to find out whether an investigational product, called LN-145, is safe and beneficial in the treatment of patients with
Non-Small-Cell-Lung-Cancer (NSCLC). LN-145 is an investigational drug. LN-145 is also called “tumor infiltrating lymphocytes” (TIL) and is made up of specialized white
blood cells called lymphocytes or “T cells” obtained from a piece of your tumor. You will undergo a tumor resection or biopsy to harvest a piece of your tumor, which will be sent to a centralized manufacturing facility where the T cells, that have infiltrated your tumor, are isolated and then grown to create the Investigational Drug LN-145, which will be infused into your body where they may attack your tumor.

This study is currently enrolling.